Grafton Therapeutics

Grafton Therapeutics is a Swiss biotechnology company focused on developing next-generation peptide therapeutics and radiopharmaceuticals for oncology and endocrine disorders. The company's proprietary approach targets both somatostatin receptor type 2 (SSTR2) and somatostatin receptor type 5 (SSTR5) simultaneously to overcome resistance to first-generation somatostatin receptor ligands. Its lead preclinical candidates, including SMTR-002, are halogenated octapeptides designed to deliver potent anti-hormonal and anti-proliferative effects in neuroendocrine tumors (NETs) and pituitary tumors. Grafton is also advancing these dual-receptor agonists as radioligand therapies (RLTs) for both diagnostic imaging and targeted cancer treatment.